ArriVent BioPharma, Inc. (AVBP) Market Cap & Valuation Ratios
ArriVent BioPharma, Inc. (AVBP) has a market cap of $1.0B, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVBPArriVent BioPharma, Inc.Follow AVBP — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| AVBP | 1.0 | — | — | — | -14.3% | — | — | -101% |
| AVLN | 1.2 | — | — | — | — | — | — | — |
| BCAX | 1.1 | — | — | — | -12.0% | — | — | -54% |
| REPL | 1.1 | — | — | — | — | — | — | -205% |
| VOR | 1.1 | — | — | — | -13.0% | — | — | — |
| MNKD | 1.0 | — | 3.1 | 41.0 | -1.8% | +30% | 2% | 4% |
| JANX | 1.0 | — | 2.0 | — | -4.1% | — | — | -16% |
| JBIO | 0.9 | — | — | — | -13.3% | — | — | -50% |
| GLUE | 0.9 | — | 29.1 | — | -3.5% | -84% | — | -61% |
| CGEM | 0.9 | — | — | — | — | — | — | -67% |
| VSTM | 0.9 | — | 9.7 | — | — | +3996% | -183% | — |
| Median of these 10 | — | 6.4 | 41.0 | -8.0% | +30% | -90% | -54% |
.
Growth vs. price
each dot a company · hover or tap for valuesArriVent BioPharma, Inc. — questions
- What is ArriVent BioPharma, Inc.'s market cap?
- $1.0B.
Every figure on this page comes from ArriVent BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.